Adial Pharmaceuticals, INC

Adial Pharmaceuticals has completed the acquisition of Azora Therapeutics, bolstering its pipeline with AT177 for ulcerative colitis and securing up to $64 million in financing.

Adial Pharmaceuticals reports Q1 2026 financial results, highlighting progress in advancing AD04 and potential regulatory advantages for Alcohol Use Disorder treatments.

Adial Pharmaceuticals reports significant regulatory progress for AD04, expanded IP, strategic partnerships, and improved 2025 financial results.

Adial Pharmaceuticals announced a collaboration framework with Molteni Farmaceutici for AD04 commercialization in Europe, potentially worth $60 million, while also reporting a failed Special Meeting of Stockholders due to lack of quorum.

Adial Pharmaceuticals announced it has regained full compliance with Nasdaq's minimum bid price requirement, advancing its AD04 program.

Adial Pharmaceuticals will effect a 1-for-25 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and attract broader investor interest.

Adial Pharmaceuticals reports a net loss of $2.0 million for Q1 2026 while continuing development of its AD04 addiction treatment candidate.

Adial Pharmaceuticals reports reduced net losses but raises substantial doubt about its ability to continue as a going concern, with cash only sufficient into Q2 2026, while navigating Nasdaq listing compliance issues.

Adial Pharmaceuticals reported reduced net losses and a significant increase in cash for Q2 2025, driven by recent capital raises, but faces ongoing going concern doubts and Nasdaq listing challenges.

Adial Pharmaceuticals reports a net loss for Q1 2025, focusing on AD04 development and securing additional funding through a warrant inducement agreement.

Adial Pharmaceuticals' Q3 2024 report reveals a significant increase in research and development expenses, alongside ongoing efforts to secure additional funding for its operations.

Adial Pharmaceuticals experienced a net loss of $2.46 million in the second quarter of 2024, driven by increased research and development expenses.

Adial Pharmaceuticals reported a net loss of $8.0 million in 2025 and faces substantial doubt about its ability to continue as a going concern, while advancing its lead drug candidate AD04 for Alcohol Use Disorder.

Adial Pharmaceuticals reports its 2024 financial results, highlighting a net loss but emphasizing strategic focus on AD04 clinical development for alcohol use disorder.

Adial Pharmaceuticals is shifting its focus to the US market for its alcohol use disorder treatment, AD04, after analyzing Phase 3 trial data and securing additional funding through warrant exercises.

Coastlands Capital LP reported changes in beneficial ownership of Adial Pharmaceuticals, Inc. common stock on July 14, 2026.

Coastlands Capital LP reported changes in beneficial ownership of Adial Pharmaceuticals, Inc. common stock on July 9, 2026.

Coastlands Capital LP reports the acquisition of 25,000 shares of ADial Pharmaceuticals, Inc. common stock.

Matt Davidson, Chief Development Officer and Director at Adial Pharmaceuticals, reports significant stock transactions following a merger.

Director Wendy B. Young of Adial Pharmaceuticals, Inc. has acquired 36,378 pre-funded warrants for common stock, as detailed in a recent SEC Form 4 filing.

Tony Goodman, Chief Operating Officer of ADial Pharmaceuticals, Inc., reported the acquisition of 26,510 shares of common stock on April 7, 2026, as part of a restricted stock grant.

Adial Pharmaceuticals, Inc. will hold a special meeting on February 26, 2026, to seek stockholder approval for the issuance of up to 13,823,512 shares of common stock related to Series F warrant exercises.

Adial Pharmaceuticals, Inc. is calling its 2025 Annual Meeting to vote on critical proposals including a reverse stock split to regain Nasdaq compliance, approval for significant warrant exercises to raise capital, and an increase in authorized shares for future flexibility.

Adial Pharmaceuticals, Inc. is calling its 2025 Annual Meeting of Stockholders to vote on critical proposals including a reverse stock split to regain Nasdaq compliance and the issuance of shares from recent warrant exercises, aiming to secure vital funding despite significant financial losses and internal control weaknesses.

Adial Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders on November 12, 2024, to vote on director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, is conducting a 'best efforts' public offering of common stock and warrants to raise up to $4.325 million, while facing substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing non-compliance.

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, is offering up to 7.59 million shares of common stock and associated warrants to raise approximately $4.325 million, as it faces significant accumulated deficits, recurring losses, and ongoing Nasdaq listing compliance issues.

Adial Pharmaceuticals has filed a registration statement for the resale of up to 5,000,000 shares of its common stock by Alumni Capital LP.

Coastlands Capital LP and affiliated entities have reported beneficial ownership of 14.22% of Adial Pharmaceuticals' common stock, totaling 373,322 shares.

Coastlands Capital LP and affiliates have reported a 9.98% beneficial ownership stake in Adial Pharmaceuticals, Inc. as of June 17, 2026.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 274,139 shares, representing 4.99% of Adial Pharmaceuticals, Inc.'s common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has filed a Schedule 13G disclosing a 2.8% beneficial ownership stake in Adial Pharmaceuticals, Inc. common stock.